Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 204

1.

Delivery of TRAIL-expressing plasmid DNA to cancer cells in vitro and in vivo using aminoglycoside-derived polymers.

Goklany S, Lu P, Godeshala S, Hall A, Garrett-Mayer E, Voelkel-Johnson C, Rege K.

J Mater Chem B. 2019 Oct 21. doi: 10.1039/c9tb01286a. [Epub ahead of print]

PMID:
31633707
2.

Understanding the Role of Advanced Practice Providers in Oncology in the United States.

Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF.

J Adv Pract Oncol. 2018 Sep-Oct;9(6):585-598. Epub 2018 Sep 1. Review.

3.

Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer.

Warren GW, Cartmell KB, Garrett-Mayer E, Salloum RG, Cummings KM.

JAMA Netw Open. 2019 Apr 5;2(4):e191703. doi: 10.1001/jamanetworkopen.2019.1703.

4.

Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.

Cherny NI, de Vries EGE, Dafni U, Garrett-Mayer E, McKernin SE, Piccart M, Latino NJ, Douillard JY, Schnipper LE, Somerfield MR, Bogaerts J, Karlis D, Zygoura P, Vervita K, Pentheroudakis G, Tabernero J, Zielinski C, Wollins DS, Schilsky RL.

J Clin Oncol. 2019 Feb 1;37(4):336-349. doi: 10.1200/JCO.18.00729. Epub 2018 Dec 17.

PMID:
30707056
5.

Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, Stella PJ, Voest E, Yost KJ, Perlmutter J, Pinto N, Kim ES, Schilsky RL.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00122. Epub 2018 Jul 11.

6.

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL.

J Natl Cancer Inst. 2019 Feb 1;111(2):118-128. doi: 10.1093/jnci/djy196.

7.

An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials.

Chiuzan C, Garrett-Mayer E, Nishimura M.

Stat Biopharm Res. 2018;10(3):185-195. doi: 10.1080/19466315.2018.1462727. Epub 2018 Apr 30.

8.

Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models.

Homer-Bouthiette C, Zhao Y, Shunkwiler LB, Van Peel B, Garrett-Mayer E, Baird RC, Rissman AI, Guest ST, Ethier SP, John MC, Powers PA, Haag JD, Gould MN, Smits BMG.

BMC Cancer. 2018 Dec 10;18(1):1233. doi: 10.1186/s12885-018-5109-8.

9.

Understanding the role of advanced practice providers in oncology in the United States.

Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF.

JAAPA. 2018 Dec;31(12):1-12. doi: 10.1097/01.JAA.0000549592.10756.4a. Review.

PMID:
30489397
10.

Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention.

Walter KR, Ford ME, Gregoski MJ, Kramer RM, Knight KD, Spruill L, Nogueira LM, Krisanits BA, Phan V, La Rue AC, Lilly MB, Ambs S, Chan K, Turner TF, Varner H, Singh S, Uribarri J, Garrett-Mayer E, Armeson KE, Hilton EJ, Clair MJ, Taylor MH, Abbott AM, Findlay VJ, Peterson LL, Magwood G, Turner DP.

Breast Cancer Res Treat. 2019 Feb;173(3):559-571. doi: 10.1007/s10549-018-4992-7. Epub 2018 Oct 27.

11.

Understanding the Role of Advanced Practice Providers in Oncology in the United States.

Bruinooge S, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF.

Oncol Nurs Forum. 2018 Nov 1;45(6):786-800. doi: 10.1188/18.ONF.786-800.

PMID:
30339144
12.

The effect of bone marrow graft composition on pediatric bone marrow transplantation outcomes.

Fabrizio V, Wahlquist A, Hill E, Williams E, Kramer C, Jaroscak J, Duong A, Garrett-Mayer E, Hudspeth M.

Pediatr Transplant. 2018 Dec;22(8):e13287. doi: 10.1111/petr.13287. Epub 2018 Aug 29.

PMID:
30159974
13.

Understanding the Role of Advanced Practice Providers in Oncology in the United States.

Bruinooge SS, Pickard TA, Vogel W, Hanley A, Schenkel C, Garrett-Mayer E, Tetzlaff E, Rosenzweig M, Hylton H, Westin SN, Smith N, Lynch C, Kosty MP, Williams SF.

J Oncol Pract. 2018 Sep;14(9):e518-e532. doi: 10.1200/JOP.18.00181. Epub 2018 Aug 22. Erratum in: J Oncol Pract. 2019 Jan;15(1):60.

PMID:
30133346
14.

Nicotine replacement therapy sampling via primary care: Methods from a pragmatic cluster randomized clinical trial.

Dahne J, Wahlquist AE, Boatright AS, Garrett-Mayer E, Fleming DO, Davis R, Egan B, Carpenter MJ.

Contemp Clin Trials. 2018 Sep;72:1-7. doi: 10.1016/j.cct.2018.07.008. Epub 2018 Jul 17.

15.

Molecular properties of gp100-reactive T-cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells.

Eby JM, Smith AR, Riley TP, Cosgrove C, Ankney CM, Henning SW, Paulos CM, Garrett-Mayer E, Luiten RM, Nishimura MI, Baker BM, Le Poole IC.

Pigment Cell Melanoma Res. 2019 Jan;32(1):68-78. doi: 10.1111/pcmr.12724. Epub 2018 Aug 13.

PMID:
30009548
16.

The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey.

Kirkwood MK, Hanley A, Bruinooge SS, Garrett-Mayer E, Levit LA, Schenkel C, Seid JE, Polite BN, Schilsky RL.

J Oncol Pract. 2018 Jul;14(7):e412-e420. doi: 10.1200/JOP.18.00149. Epub 2018 Jun 15.

PMID:
29906211
17.

Preoperative predictors of occult nodal disease in cT1N0 oral cavity squamous cell carcinoma: Review of 2623 cases.

Zhan KY, Morgan PF, Neskey DM, Kim JJ, Huang AT, Garrett-Mayer E, Day TA.

Head Neck. 2018 Sep;40(9):1967-1976. doi: 10.1002/hed.25178. Epub 2018 May 14.

PMID:
29761586
18.

A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.

Thomas MB, Garrett-Mayer E, Anis M, Anderton K, Bentz T, Edwards A, Brisendine A, Weiss G, Siegel AB, Bendell J, Baron A, Duddalwar V, El-Khoueiry A.

Oncology. 2018;94(6):329-339. doi: 10.1159/000485384. Epub 2018 May 2.

PMID:
29719302
19.

Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.

Omuro A, Beal K, McNeill K, Young RJ, Thomas A, Lin X, Terziev R, Kaley TJ, DeAngelis LM, Daras M, Gavrilovic IT, Mellinghoff I, Diamond EL, McKeown A, Manne M, Caterfino A, Patel K, Bavisotto L, Gorman G, Lamson M, Gutin P, Tabar V, Chakravarty D, Chan TA, Brennan CW, Garrett-Mayer E, Karmali RA, Pentsova E.

J Clin Oncol. 2018 Jun 10;36(17):1702-1709. doi: 10.1200/JCO.2017.76.9992. Epub 2018 Apr 23.

20.

Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells.

Johnson CB, May BR, Riesenberg BP, Suriano S, Mehrotra S, Garrett-Mayer E, Salem ML, Jeng EK, Wong HC, Paulos CM, Wrangle JM, Cole DJ, Rubinstein MP.

Cancer Res. 2018 Jun 1;78(11):3067-3074. doi: 10.1158/0008-5472.CAN-17-2153. Epub 2018 Apr 10.

Supplemental Content

Loading ...
Support Center